

## LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W** 

WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 08/18/2023 10:45 Received: 08/18/2023 10:45

Test Name Result Flag Ref-Ranges Units Site

Anti-Ri (antineuronal nuclear antibody, type 2)

Interpretation See Note QCRL

NEGATIVE

This test did not detect abnormal levels of anti-Ri antibodies.

Technical Results See Note QCRL

\_\_\_\_\_

Interpretive Result Table

\_\_\_\_\_

INTERPRETIVE RESULT: Negative

TEST: anti-Ri

TECHNICAL RESULT: <1:50

REFERENCE RANGE: Serum <1:50

\_\_\_\_\_

Methods See Note QCRL

Detection of antibodies was performed by automated nanoliter scale immunoassay.

Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.

Comments See Note QCRL

Comments: This result does not exclude a diagnosis of an autoimmune etiology for the neurological symptoms associated with paraneoplastic disorder.

Recommendations: Health care providers, please contact the Athena Diagnostics Client Services Department at 1-800-394-4493 if you wish to speak with a clinical consultant regarding this test result.

Other testing available: Athena Diagnostics currently offers the following antibody tests: anti-amphiphysin, anti-CASPR2, anti-CV2, anti-GAD65, anti-ganlionic nAChR, anti-Hu, anti-LGI1, anti-Ma, anti-Ta, anti-NMDA, anti-Recoverin, anti-VGCC, anti-VGKC, anti-Yo, and anti-Zic4. Please contact the Athena Diagnostics Client Services Department or visit AthenaDiagnostics.com for information regarding additional testing that may be appropriate based on this individual's

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL,  $\,$  . - NOT TESTED

F218000036 WX0000003827 Printed D&T: 08/18/23 10:46 Ordered By: KAJAL SITWALA, MD, PhD WX00000000002354



## LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W** 

WX0000003827 M 07/08/1978 45 Y

**Referral Testing** 

Collected: 08/18/2023 10:45 Received: 08/18/2023 10:45

<u>Test Name</u> <u>Result</u> <u>Flag Ref-Ranges</u> <u>Units</u> <u>Site</u>

clinical presentation.

Background information: Paraneoplastic neurological syndromes or disorders (PNS or PND) are rare immune-mediated disorders resulting from nervous system damage due to the remote effects of a tumor. PND of the central nervous system may occur in association with either onconeural antibodies directed against intracellular antigens, or antibodies targeted against neuronal surface antigens. These autoantibodies have been associated with various clinical presentations and malignancies.

References See Note QCRL

1. Titulaer, MJ, et al. (2011) Eur J Neurol 18: 19-e3. (PMID: 20880069) 2. Zuliani, L, et al. (2012) J Neurol Neurosurg Psychiatry 83: 638-45. (PMID: 22448032)

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Laboratory oversight provided by Vivekananda Datta, M.D., Ph.D., CLIA license holder, Athena Diagnostics (CLIA# 22D0069726)

Testing performed at:
Athena Diagnostics 200 Forest Street Marlborough, MA 01752
Test Performed at:
Athena Diagnostics, Inc.
200 Forest Street, 2nd Floor
Marlborough, MA 01752 V Datta MD, PhD

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.08.18 10:45 RI

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F218000036 WX0000003827 Printed D&T: 08/18/23 10:46 Ordered By: KAJAL SITWALA, MD, PhD WX00000000002354